- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Synokem Pharmaceutical Gets CDSCO Panel Nod To Study Anti-rheumatoid drug Iguratimod

New Delhi: Suggesting to specify the eGFR (Modification of Diet in Renal Disease Formula) or chronic kidney disease (CKD) stage in the exclusion criteria, the Subject Expert Committee SEC functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to Synokem Pharmaceuticals to conduct a Phase IV clinical trial of iguratimod tablets 25 mg.
However, in addition to the above, the committee opined the firm that serum NT-proBNP be included as a screening tool for significant cardiovascular disease.
This came after the firm presented Phase IV Clinical Trial Protocol No. CT22-005, Version No. 01, dated 03.12.2022, before the committee.
Iguratimod (IGU) is a disease-modifying anti-rheumatic drug (DMARD) that treats rheumatoid arthritis (RA) and other autoimmune diseases. It's also used to treat ankylosing spondylitis, interstitial lung disease, and other rheumatic diseases.
Iguratimod inhibits citrulline protein expression in neutrophils of patients with rheumatoid arthritis at an appropriate concentration, similar to MTX and dexamethasone; the inhibitory effect is mediated by the down-regulation of peptidylarginine deiminase.
At the recent SEC meeting for analgesics and rheumatology held on February 25, 2025, the expert panel reviewed Phase IV Clinical Trial Protocol No. CT22-005, version No. 01, dated 03.12.2022.
After detailed deliberation, the committee recommended conducting a Phase IV clinical trial as per the protocol presented by the firm with the following changes:
- Firm need to specify the eGFR (MDRD formula) or CKD stage in the exclusion criteria, serum NT-proBNP to be included as screening tool for significant cardiovascular disease.
Accordingly, the expert panel suggested that the firm should submit the revised protocol to CDSCO.
Also Read:Mylan Pharmaceutical Gets CDSCO Panel Nod To study Selatogrel
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.